Prevalence of CD8(+) cytotoxic lymphocytes in human neoplasms

PURPOSE: Immune checkpoint inhibitors have recently been approved by the US FDA as first and/or second line therapy in a subset of cancer types. Recent evidence suggests that the quantity of tumor infiltrating lymphocytes (TILs) influences the likelihood of response to immune checkpoint inhibitors....

Descripción completa

Detalles Bibliográficos
Autores principales: Blessin, Niclas C., Spriestersbach, Patrick, Li, Wenchao, Mandelkow, Tim, Dum, David, Simon, Ronald, Hube-Magg, Claudia, Lutz, Florian, Viehweger, Florian, Lennartz, Maximillian, Fraune, Christoph, Nickelsen, Vera, Fehrle, Wilfried, Göbel, Cosima, Weidemann, Sören, Clauditz, Till, Lebok, Patrick, Möller, Katharina, Steurer, Stefan, Izbicki, Jacob R., Sauter, Guido, Minner, Sarah, Jacobsen, Frank, Luebke, Andreas M., Büscheck, Franziska, Höflmayer, Doris, Wilczak, Waldemar, Burandt, Eike, Hinsch, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214387/
https://www.ncbi.nlm.nih.gov/pubmed/32141029
http://dx.doi.org/10.1007/s13402-020-00496-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214387/
https://www.ncbi.nlm.nih.gov/pubmed/32141029
http://dx.doi.org/10.1007/s13402-020-00496-7

Ejemplares similares